Answers are grounded in this paper and cite their sources.
B-cell chronic lymphocytic leukemia (B-CLL) and autoimmune disease are a related event, and genetic factors are linked to both diseases. As B-CLL is mainly of B-1 cell type that participates in autoantibody production, genetically-determined regulatory abnormalities in proliferation and/or differentiation of B-1 cells may determine their fate. We earlier found that, in H-2-congenic (NZB x NZW) F1 mice, while H-2(d/z) heterozygosity predisposes to autoimmune disease, H-2(z/z) homozygosity predisposes to B-CLL. Studies also suggested the involvement of non-H-2-linked NZW allele(s) in leukemogenesis. Using H-2-congenic NZW and B10 mouse strains, their F1 and backcross progeny, we have now identified three major NZW susceptibility loci for abnormal proliferation of B-1 cells, which form the basis of leukemogenesis; one H-2-linked locus on chromosome 17 and the other two non-H-2-linked loci, each on chromosome 13 and chromosome 17. Each susceptibility allele functioned independently, in an incomplete dominant fashion, the sum of effects determining the extent of aberrant B-1 cell frequencies. The development of leukemia was associated with age-related increase in B-1 cell frequencies in the blood. Thus, these alleles probably predispose B-1 cells to accumulate genetic alterations, giving rise to B-CLL. Potentially important candidate genes and correlation of the findings with autoimmune disease are discussed.
No takes yet. Share an insight, caveat, or question.
Hamano et al. (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: